These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21309055)

  • 1. Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study.
    Monnier L; Colette C; Michel F; Cristol JP; Owens DR
    Diabetes Metab Res Rev; 2011 May; 27(4):348-53. PubMed ID: 21309055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
    Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy.
    Monnier L; Colette C; Mas E; Michel F; Cristol JP; Boegner C; Owens DR
    Diabetologia; 2010 Mar; 53(3):562-71. PubMed ID: 19890623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Correlation Between Urinary 8-Iso-Prostaglandin F2α and Hydrogen Peroxide Toward Renal Function in T2DM Patients Consuming Sulfonylurea and Combination of Metformin-Sulfonylurea.
    Sauriasari R; Wulandari F; Nurifahmi R; Sekar AP; Susilo VY
    Curr Diabetes Rev; 2018; 14(2):189-195. PubMed ID: 27981897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus.
    Wang Y; Gong C; Cao B; Meng X; Wei L; Wu D; Liang X; Li W; Liu M; Gu Y; Su C
    Pediatr Diabetes; 2017 May; 18(3):196-203. PubMed ID: 26947770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Joya-Galeana J; Fernandez M; Cervera A; Reyna S; Ghosh S; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
    Raccah D; Gourdy P; Sagnard L; Ceriello A
    Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
    Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
    Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
    Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
    Hanefeld M; Pfützner A; Forst T; Kleine I; Fuchs W
    Cardiovasc Diabetol; 2011 Jul; 10():65. PubMed ID: 21756323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
    Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
    Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M; Swatko A; Hilberg C; Shestakova M
    Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.